MINNEAPOLIS, MN / ACCESSWIRE / February 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the fourth quarter and fiscal year 2020 after the stock market close on Tuesday, February 16, 2021. Management will host a teleconference the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.
Conference Call Details
Participants should dial 1-866-831-8616 and use passcode 92066. Participants are asked to dial in 5 to 10 minutes prior to the start of the call.
About Celcuity
Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's proprietary CELsignia diagnostic platform analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. We are driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.
Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including the anticipated benefits to the clinical outcomes of cancer patients. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, those set forth in the Risk Factors section of Celcuity's Annual Report on Form 10-K for the year ended December 31, 2019. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contacts:
Celcuity Inc.
Brian Sullivan, [email protected]
Vicky Hahne, [email protected]
SOURCE: Celcuity Inc.